Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $229.0 million.

  • Keros Therapeutics' Net Cash Flow fell 97.40% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.8 million, marking a year-over-year decrease of 33.02%. This contributed to the annual value of $229.0 million for FY2024, which is 340.56% up from last year.
  • Latest data reveals that Keros Therapeutics reported Net Cash Flow of $229.0 million as of FY2024, which was up 340.56% from $52.0 million recorded in FY2023.
  • Keros Therapeutics' Net Cash Flow's 5-year high stood at $258.9 million during FY2020, with a 5-year trough of -$34.6 million in FY2021.
  • Over the past 3 years, Keros Therapeutics' median Net Cash Flow value was $52.0 million (recorded in 2023), while the average stood at $110.0 million.
  • As far as peak fluctuations go, Keros Therapeutics' Net Cash Flow soared by 1,692.47% in 2020, and later crashed by 113.38% in 2021.
  • Yearly analysis of 5 years shows Keros Therapeutics' Net Cash Flow stood at $258.9 million in 2020, then plummeted by 113.38% to -$34.6 million in 2021, then soared by 241.55% to $49.0 million in 2022, then rose by 6.08% to $52.0 million in 2023, then spiked by 340.56% to $229.0 million in 2024.